vida: extract claims from 2025-pmc-ai-recessionary-pressures-population-health

- Source: inbox/queue/2025-pmc-ai-recessionary-pressures-population-health.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md

@@ -26,3 +26,10 @@ Critical methodological limitations constrain interpretation: this is an observa
 **Source:** PHTI Employer GLP-1 Coverage Market Trend Report, December 2025
 
 Employer payers are adopting tiered coverage models that bundle GLP-1 drugs with behavioral programs versus drug-only coverage. PHTI reports employers moving from 'cover the drug' to 'cover the drug + support program' to manage cost and outcomes. This payer adoption pattern validates the behavioral support necessity thesis—the market is making support programs a coverage requirement, not an optional add-on.
+
+
+## Supporting Evidence
+
+**Source:** JMIR 2025 + 65,000-user hybrid coaching dataset
+
+Digital behavioral support achieving 18.4% weight loss (matching clinical trial outcomes) with integrated coaching provides evidence that behavioral wraparound can maintain outcomes during active treatment. The 74% improvement from human-AI hybrid over AI-only coaching suggests the human accountability layer is the active ingredient in behavioral durability.

domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md

@@ -0,0 +1,20 @@
+---
+type: claim
+domain: health
+description: Combination of pharmacotherapy with digital behavioral programs achieves clinical-trial-level outcomes in real-world settings
+confidence: experimental
+source: JMIR 2025 (e69466) + Omada Health Enhanced GLP-1 Care Track real-world data
+created: 2026-04-27
+title: "Digital behavioral support improves GLP-1 persistence by 20 percentage points (67% vs 47% at 12 months) through integrated coaching and monitoring"
+agent: vida
+sourced_from: health/2025-jmir-glp1-digital-coaching-adherence-67pct.md
+scope: causal
+sourcer: JMIR / Omada Health
+supports: ["healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create"]
+challenges: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics"]
+related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-long-term-persistence-ceiling-14-percent-year-two"]
+---
+
+# Digital behavioral support improves GLP-1 persistence by 20 percentage points (67% vs 47% at 12 months) through integrated coaching and monitoring
+
+Two converging data sources demonstrate that digital behavioral support substantially improves GLP-1 medication persistence. Omada Health's Enhanced GLP-1 Care Track showed 67% of members persistent on medication at 12 months, compared to baseline real-world evidence of 47-49% persistence without digital support—a 20 percentage point improvement. The JMIR 2025 peer-reviewed study (e69466) independently confirmed that engagement with digital weight management platforms significantly enhances weight loss outcomes among GLP-1 users. Weight loss outcomes also improved: 18.4% average weight loss with digital support versus 11.9% in standard real-world evidence, matching clinical trial results. A ~65,000-user dataset showed hybrid human-AI coaching produced 74% more weight loss than AI-only coaching over 3 months, suggesting the human coaching layer drives marginal adherence improvement. The mechanism appears to be behavioral support addressing the non-pharmacological barriers to persistence: side effect management, lifestyle integration, and accountability. This is distinct from the drug's pharmacological effect and represents a separable value layer. Important caveat: The 67% figure comes from Omada's proprietary platform data, not independent verification, though the JMIR peer-reviewed paper provides directional corroboration.

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -5,30 +5,13 @@ description: "Two-year real-world data shows only 15% of non-diabetic obesity pa
 confidence: likely
 source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
 created: 2026-03-11
-related_claims:
-  - divergence-glp1-economics-chronic-cost-vs-low-persistence
-depends_on:
-- GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035
-challenges:
-- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
-- GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management
-- Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?
-reweave_edges:
-- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|challenges|2026-04-04
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation|related|2026-04-09
-- GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements|supports|2026-04-09
-- GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|challenges|2026-04-09
-- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|related|2026-04-14
-- Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?|challenges|2026-04-17
-- GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use|related|2026-04-24
-supports:
-- GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements
-related:
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
-- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
-- GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use
-sourced_from:
-- inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md
+related_claims: ["divergence-glp1-economics-chronic-cost-vs-low-persistence"]
+depends_on: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
+challenges: ["GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability", "GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?"]
+reweave_edges: ["GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|challenges|2026-04-04", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation|related|2026-04-09", "GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements|supports|2026-04-09", "GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|challenges|2026-04-09", "Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|related|2026-04-14", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?|challenges|2026-04-17", "GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use|related|2026-04-24"]
+supports: ["GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements"]
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement", "GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "divergence-glp1-economics-chronic-cost-vs-low-persistence"]
+sourced_from: ["inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md"]
 ---
 
 # GLP-1 persistence drops to 15 percent at two years for non-diabetic obesity patients undermining chronic use economics
@@ -150,4 +133,10 @@ Relevant Notes:
 - [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
 
 Topics:
-- domains/health/_map
+- domains/health/_map
+
+## Challenging Evidence
+
+**Source:** JMIR 2025 (e69466) + Omada Health real-world data
+
+Omada Health's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months (vs. 47-49% baseline) through integrated digital behavioral support, suggesting low persistence rates may be addressable through intervention design rather than being an immutable patient characteristic. The 20 percentage point improvement demonstrates that the structural intervention opportunity is substantial.

domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md

@@ -10,7 +10,7 @@ agent: vida
 scope: causal
 sourcer: Tzang et al. (Lancet eClinicalMedicine)
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
-related: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms"]
+related: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms", "glp1-response-variability-partially-genetically-determined-glp1r-gipr-variants-predict-weight-loss-and-side-effects"]
 reweave_edges: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks|related|2026-04-09", "GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12", "Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|challenges|2026-04-14"]
 supports: ["GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales"]
 challenges: ["Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement"]
@@ -46,3 +46,10 @@ The continuous treatment requirement extends beyond metabolic conditions to subs
 **Source:** WHO Global Guideline, December 2025
 
 WHO guideline specifies GLP-1 therapies for 'long-term obesity treatment (defined as ≥6 months continuous therapy)' and cites 'unclear maintenance and discontinuation protocols' as a reason for conditional rather than strong recommendation, confirming the chronic use requirement
+
+
+## Supporting Evidence
+
+**Source:** eClinicalMedicine/Lancet 2025 systematic review and meta-analysis (PMC12535773)
+
+Meta-analysis of discontinuation studies shows weight regain is proportional to original weight loss: liraglutide patients regained 2.20 kg, while semaglutide/tirzepatide patients regained 9.69 kg. Most patients regain two-thirds of prior weight loss within 6 months of stopping. Cardiometabolic benefits (blood pressure, lipids, CVD risk) reverse along with weight regain, confirming that GLP-1 suppression of appetite is pharmacological rather than behavioral modification. When drug is withdrawn, underlying neurobiological hunger signals return to baseline.

domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md

@@ -37,3 +37,10 @@ Cell/Med 2025 connects low persistence rates to the sustainability concern: chro
 **Source:** PHTI Employer GLP-1 Coverage Market Trend Report, December 2025
 
 PHTI December 2025 report documents employer payer response to low GLP-1 persistence: movement toward bundled coverage requiring behavioral support programs as a condition of drug coverage. Employers are framing GLP-1 coverage without personal support as 'wasted wellness dollars' (Benefits Pro, March 2026). This represents the market mechanism translating adherence data into coverage architecture—payers are structurally responding to the persistence problem by mandating behavioral wraparound rather than covering drugs alone.
+
+
+## Extending Evidence
+
+**Source:** eClinicalMedicine/Lancet 2025 discontinuation meta-analysis
+
+The biological mechanism underlying low persistence creates a clinical revolving door: when patients discontinue (which 85% do by year two), they regain two-thirds of lost weight within 6 months. For semaglutide/tirzepatide users, mean regain is 9.69 kg. This means the 14% persistence ceiling isn't just an adherence problem—it's a structural barrier to population health impact, as discontinued patients return to near-baseline metabolic state within months.

inbox/archive/health/2025-jmir-glp1-digital-coaching-adherence-67pct.md

@@ -7,9 +7,12 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: peer-reviewed study
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-27
 priority: high
 tags: [glp-1, digital-health, adherence, behavioral-support, coaching, obesity, persistence, atoms-to-bits, value-based]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2025-lancet-eclinmed-glp1-weight-regain-meta-analysis.md

@@ -7,9 +7,12 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: peer-reviewed meta-analysis
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-27
 priority: high
 tags: [glp-1, weight-regain, discontinuation, metabolic-rebound, semaglutide, tirzepatide, chronic-disease, adherence]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content